MD, Consultant Gastrointestinal Oncology and Gastroenterology, Universitair Ziekenhuis Leuven | Colon Cancer research at Tejpar lab | @UZLeuven @KU_Leuven
Brussels, Belgium
Joined September 2011
- Tweets111
- Following292
- Followers241
- Likes317
Gertjan Rasschaert retweeted
🚨 STELLAR-303 makes history! First-ever Ph3 trial to show OS benefit of IO in MSS CRC 🎯
Years of grit & belief led us here 🥹
Endless thanks to Exelixis for the trust & Dr. Hecht for leading this global win with me! 🎉 @UPMCHillmanCC ir.exelixis.com/news-release…
🧐 Can you predict who’s responding to #BOTBAL and who isn’t? Discover it next week at #ASCO25!
🙋♂️ See you on:
Saturday 31st of May, 09:00AM to 12:00PM #CRC poster session, Hall A
Poster Bd 196 - Abstract No 3527
@UZLeuven @KU_Leuven @OmniscopeAI @Agenus_Bio @ASCO
Looking back at a fruitfull 2 days at the @EORTC GI tract cancer group ‘spring meeting’ that we hosted at @KU_Leuven. The first day was all about academic research collaboration. While today we had a scientific symposium on the #neoadjuvant space in GI cancers.
@FilipHerpe
⏱️ Timing couldn’t be better. Today I will give a lecture on the growing problem of early onset CRC at the yearly symposium of our residents in internal medicine at @KU_Leuven / @UZLeuven
#EOCRC, @CCAlliance, @FightCRC, @StopDarmkanker, @LKILeuven
#CRC highlights from @ASCO #GI25:
#8HW, #breakwater, #alascca, #bespoke, #botbal metastatic and neoadjuvant, @Agenus_Bio, etc.
Bridging towards our now open #AZUR4 @GSK neoadjuvant trial in #pMMR #MSS CRC at @UZLeuven
🚨Highlights from #ASCOGI2025! Dr @GJRas unveils key advances in colorectal cancer. From immunotherapy breakthroughs to predictive biomarkers and preventive strategies, catch all the latest insights.
Next time, I need some ‘fond de teint’ to cover up the jet lag marks 🥲
🚨Poster from #ASCOGI2025! Dr @GJRas presents a novel IS-IC model to predict ICB response in mCRC.
🔹 High-score groups show ICB-sensitive stroma.
🔹 Multiplex immunofluorescence confirms biomarker validity.
Immunosensitivity cuts across mismatch repair status in colorectal cancer
Our preview article on the recent Acha-Sagredo et al. has been published today in @Cancer_Cell.
shorturl.at/uJ8av
Gertjan Rasschaert retweeted
🎆 Now online - my 2 fav topics in one paper
👍FOxTROT Ph2 FOLFOX+/- pani in locally advanced RAS/RAF-wt colon cancer
👍Convincing activity of anti-EGFR on long term outcomes, esp in hyperselected pts
❓Time to re-think targeted agents in LACC/LARC
annalsofoncology.org/article…
👇
We have compared the performance ctDNA by Natera vs. imaging in curatively resected colorectal cancer on surveillance. Signatera missed 31% of recurrences (+ imaging and negative Signatera). Largest study of comparative strategies. jamanetwork.com/journals/jam…
🔪Salvage surgery for unifocal progressive metastatic dMMR GI cancer responding to #ICI
ascopubs.org/doi/10.1200/PO.…
Interesting new article in @JCOPO_ASCO from our @UZLeuven / @KU_Leuven team. 💪
@JDekervel, @FilipHerpe, @iBakiTopal, @deroose_c, @decaesteckerj, @WolthuisA et al.
👆🏽Save the date: 05-06 December, Towards New Standards in Colorectal Cancer.
✍️ Registration:
etr.events/towardsnewstandar…
👥👥 @UZLeuven CRC MDT:
@DhooreAndre, Sabine Tejpar, @WolthuisA, @JDekervel, @jaekersj, @FilipHerpe, @GJRas, @bisle84, et al.
Gertjan Rasschaert retweeted
Where innovation crosses boundaries! Final countdown has started! If you haven’t registered yet, register today! Looking forward welcoming you soon in Leuven for our International Congress! @ibdleuven @SeverineVermei1 @JoaoPGSabino @DhooreAndre @bisle84
ibdleuven2024.com
Join us for the #IBD Leuven international congress! Time is running fast, early bird registration ends June 2nd! Explore our program now! An exciting 3 day program filled with many (inter)national speakers !
ibdleuven2024.com
1/2 Very interesting work by Zemin Zhang and esteemed colleagues tracking immune dynamics of #CRC patients under PD-1 blockade.
cell.com/cancer-cell/fulltex…
2/2 However still real-world study... Hetererogenous small population (N= 22) both dMMR/MSI & pMMR/MSS tumors. Not clear who received ICB only, who received combination with chemotherapy.
Future prospective studies are coming!
@Cancer_Cell @CellCellPress @PKU1898
Gertjan Rasschaert retweeted
How to advise patients with poor response on interim MRI after induction CRT in TNT? 🤔
Among 40 patients in our series 2015-2021 with interim mrTRG4:
🔵 2 sustained cCR after consolidation chemo
🔵Of 38 TME, 10 (26%) had pCR
🔵 Recommend completion of TNT
#ESMOGI24
